GHK-Cu Research Profile: Copper Peptide Studies on Skin Repair, Hair Growth, and Aging

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide first isolated from human plasma by Loren Pickart in 1973. It has since become one of the most widely referenced peptides in dermatological and aging research. This profile from the Peptide Register summarises what the published literature shows, with attention to evidence quality and regulatory context.

What Is GHK-Cu and How Does It Work?

GHK-Cu is a tripeptide composed of three amino acids, glycine, histidine, and lysine, bound to a copper(II) ion. GHK-Cu is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine. Its concentration in human plasma has been reported to decline with age, from approximately 200 ng/mL at age 20 to roughly 80 ng/mL by age 60, according to work by Pickart and colleagues.

The proposed mechanisms of action are broad. In vitro and animal studies suggest GHK-Cu may modulate expression of genes involved in collagen synthesis, antioxidant defence, inflammation, and tissue remodelling. A 2014 gene expression analysis by Campbell et al. reported that GHK-Cu influenced the expression of over 4,000 human genes in cell culture models. This finding, while notable, has not been independently replicated in large-scale human studies.

For readers newer to peptide science, the Peptide Register glossary provides definitions of key terms such as tripeptide, copper-binding ligand, and signal peptide.

Skin Repair and Anti-Aging Research

Much of the published GHK-Cu literature focuses on skin. Multiple in vitro studies have reported that GHK-Cu stimulates collagen type I and III synthesis in fibroblast cultures. GHK-Cu has been reported to stimulate collagen synthesis and reduce fine wrinkle depth in small controlled human studies.

A 2009 double-blind study by Leyden et al. involving 67 women found that topical application of GHK-Cu cream over 12 weeks reduced fine lines and improved skin density compared to placebo and a vitamin C control. However, this remains one of the few randomised controlled trials in humans, and the sample size was modest.

GHK-Cu has also been studied in wound healing contexts. Animal studies have reported accelerated wound closure and increased angiogenesis following GHK-Cu application. Researchers interested in wound healing peptides may also find relevant context in our overview of Thymosin Beta-4 and wound healing research, another peptide studied for tissue repair.

It is important to note that most skin repair findings come from in vitro work and small clinical trials. Large-scale, multi-centre human RCTs for GHK-Cu in skin repair remain absent from the literature as of 2025.

Hair Growth Evidence

GHK-Cu has attracted attention for potential effects on hair follicle cycling. In vitro studies suggest GHK-Cu may promote proliferation of dermal papilla cells, which play a role in hair growth regulation. GHK-Cu has shown stimulatory effects on dermal papilla cells in vitro, but human hair growth trials remain limited.

A small number of proprietary studies have reported improvements in hair density and thickness following topical GHK-Cu use, but peer-reviewed, independent human trials specifically examining hair growth outcomes are scarce. Most evidence in this area is preclinical or comes from formulations where GHK-Cu is combined with other active ingredients, making it difficult to isolate the peptide's contribution.

Regulatory Status and Evidence Limitations

GHK-Cu is not FDA-approved as a drug for any indication. In cosmetic formulations, copper peptides including GHK-Cu are used in over-the-counter products in many jurisdictions, but therapeutic claims are not permitted without regulatory approval. In Australia, peptides with therapeutic claims fall under TGA scheduling requirements, and GHK-Cu's classification depends on its intended use and delivery method.

GHK-Cu is not approved by the FDA as a therapeutic drug for any indication as of 2025. Researchers and clinicians should be aware that the regulatory landscape for peptides is evolving. The Peptide Register tracks these changes across jurisdictions through our peptide database and regulatory monitoring tools.

Several important caveats apply to the GHK-Cu evidence base overall. The 2014 gene expression study reported GHK-Cu influenced over 4,000 human genes, but this was observed in cell culture, not in vivo. Many promising wound healing results come from animal models, primarily rodent studies, and translation to human outcomes is uncertain. The hair growth literature lacks independent, adequately powered randomised trials. Long-term safety data for injectable or high-concentration topical GHK-Cu formulations are limited.

GHK-Cu plasma concentration reportedly declines from approximately 200 ng/mL at age 20 to 80 ng/mL by age 60. Whether this decline is causally related to aging phenotypes or merely correlational remains an open question.

Summary

GHK-Cu is among the most studied copper peptides in dermatological research, with a mechanistic profile spanning collagen synthesis, gene modulation, and wound repair. However, the evidence base is heavily weighted toward in vitro and animal studies. The small number of human RCTs, while promising in direction, are insufficient to support definitive conclusions. As with all peptides catalogued by the Peptide Register, readers should evaluate the primary literature carefully and consider the guidance on reading peptide research when assessing study quality.